Predict your next investment

Corporation
vivionebiosciences.com

See what CB Insights has to offer

Partners & Customers

2

About Vivione Biosciences

Vivione is a biosciences company focused on the commercialization of proprietary RAPID-B system, an integrated system of hardware, software and chemical reagents that quickly and accurately identifies, quantifies and qualifies bacteria and other pathogens in food safety, bio-therapeutics, clinical, industrial and oil and gas environments.

Vivione Biosciences Headquarter Location

5001 Spring Valley Road Suite 500W

Dallas, Texas, 75244,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Vivione Biosciences News

Vivione Biosciences, Inc. Announces Change in Board of Directors

Jan 7, 2017

Announces Change in Board of Directors   * Calgary - Alberta - Canada CALGARY, Alberta - Jan. 7, 2017 - PRLog -- Vivione Biosciences Inc. ("Vivione" or the "Corporation") (TSXV: VBI)is pleased to announce the Board of Directors has appointed Tun Myo of Little Calgary, Alberta to fill an unfilled director position. Company director Dr. James Hendren has resigned as director. Stock Exchange Listing It is expected that with the action, the Corporation meets its requirement for requisite percentage of Canadian Board Members. About Vivione Vivione's business through its ownership in VBL is centered on the commercialization of the RAPID-B technology, which is an integrated system of hardware, software and chemical reagents that tests bacteria in key environments. This technology could have potentially diverse applicability from food safety to clinical diagnostics, by identifying and quantifying microorganism levels more rapidly and with greater precision than currently employed techniques. For further information please contact: Vivione Biosciences Inc.          mark@diggsandassociates.com Cautionary Statements This news release contains "forward-looking statements" within the meaning of applicable securities laws. Although Vivione believes that the expectations reflected in its forward-looking statements are reasonable, such statements have been based on factors and assumptions concerning future events that may prove to be inaccurate. These factors and assumptions are based upon currently available information to Vivione. Such statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include the inability to close the Initial Investment, failure to reach one or all Milestones, failure to close all or part of the Follow-on Investment, the failure to receive final TSXV approval, insufficient shareholder approval, obtaining any necessary approval from regulators in the United States, and the ability of the Corporation to pays its liabilities as they become due. Readers are cautioned to not place undue reliance on forward-looking statements. The statements in this press release are made as of the date of this release and, except as required by applicable law, Vivione does not undertake any obligation to publicly update or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise. Vivione undertakes no obligation to comment on expectations or statements made by third-parties in respect of Vivione, or its financial or operating results or (as applicable), their securities. NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Vivione Biosciences Acquisitions

1 Acquisition

Vivione Biosciences acquired 1 company. Their latest acquisition was Trillium Diagnostics on January 28, 2015.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

1/28/2015

$99M

Acquired

1

Date

1/28/2015

Investment Stage

Companies

Valuation

$99M

Total Funding

Note

Acquired

Sources

1

Vivione Biosciences Partners & Customers

2 Partners and customers

Vivione Biosciences has 2 strategic partners and customers. Vivione Biosciences recently partnered with IEH on July 7, 2014.

Date

Type

Business Partner

Country

News Snippet

Sources

7/8/2014

Partner

United States

Vivione Signs Strategic Alliance Agreement with IEH and Launches New Oil and Gas Product Offerings

`` The strategic alliance with IEH agreement is a big win for us , '' said Vivione Biosciences 's Chief Executive Officer Kevin Kuykendall .

1

2/12/2014

Partner

South Korea

Subscribe to see more

Subscribe to see more

10

Date

7/8/2014

2/12/2014

Type

Partner

Partner

Business Partner

Country

United States

South Korea

News Snippet

Vivione Signs Strategic Alliance Agreement with IEH and Launches New Oil and Gas Product Offerings

`` The strategic alliance with IEH agreement is a big win for us , '' said Vivione Biosciences 's Chief Executive Officer Kevin Kuykendall .

Subscribe to see more

Subscribe to see more

Sources

1

10

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.